Lv1
30 积分 2025-09-02 加入
Effects of microplastics and nanoplastics on the kidney and cardiovascular system
15天前
已完结
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
1个月前
已完结
GLP-1 and the renin-angiotensin-aldosterone system
1个月前
已完结
Cardiovascular Risk Reduction With GLP-1 RA Drugs
1个月前
已完结
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
1个月前
已完结
Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk
1个月前
已完结
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
1个月前
已关闭
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
1个月前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Efimosfermin, a Fibroblast Growth Factor 21 Analogue for Metabolic Dysfunction-Associated Steatohepatitis
1个月前
已关闭
皖公网安备34019202002308
